Biotech

All Articles

FDA areas Kezar lupus trial in hold following 4 individual deaths

.The FDA has placed Kezar Life Sciences' lupus test on grip after the biotech flagged 4 deaths throu...

Phase 3 Historian Rock test reaches SMA target, sending out stock up 200%

.A stage 3 trial of Historian Rock's spine muscle degeneration (SMA) applicant has actually hit its ...

CAMP 4 is newest to eye IPO, while Upstream point out $182M strategy

.RNA biotech CAMP4 Rehabs has defined plans for a $67 thousand IPO, along with inflammation-focused ...

Galecto gets leukemia drug, falls bone cancer asset in pivot

.A year after the failure of an idiopathic pulmonary fibrosis prospect sent out Galecto on a hunt fo...

Judo throws down $100M to knock senseless kidney condition

.Taking the floor covering is Judo Bio, an up-and-coming biotech armed with $one hundred thousand to...

AstraZeneca pays out CSPC $100M for preclinical heart disease medicine

.AstraZeneca has paid CSPC Drug Group $100 thousand for a preclinical heart disease drug. The offer,...

Zephyrm looks for Hong Kong IPO to cash period 3 cell therapy trials

.Zephyrm Bioscience is gusting toward the Hong Kong stock exchange, submission (PDF) for an IPO to m...

Frazier Lifestyle Sciences collects $630M for tiny, mid-cap biotechs

.Frazier Life Sciences has actually sourced an even further $630 thousand for its own fund paid atte...

GigaGen amasses approximately $135M BARDA dollars to hammer botulism

.Antibody enthusiast GigaGen, a subsidiary of Spanish biopharma Grifols, is increase its own technol...

GPCR agency Septerna declare IPO on strength of preclinical data

.Septerna will find out how a biotech without "any kind of meaningful scientific records" meals in t...